Changes in Abdominal Fat following Antiretroviral Therapy Initiation in HIV-Infected Individuals Correlate with Waist Circumference and Self-Reported Changes

Abstract

Background

We examined whether waist circumference (WC) and self-reported abdominal size changes can estimate visceral adipose tissue (VAT) changes for those initiating antiretroviral therapy (ART).

Methods

Prospectively collected data from ACTG A5257 and its metabolic substudy, A5260s, were used for this analysis. ART-naive HIV-infected participants were randomized to one of three contemporary ART regimens. Changes in abdominal CT-measured VAT and total adipose tissue (TAT) and DXA-measured trunk fat were tested for association with WC changes (by Pearson correlation) and categories of self-reported abdominal size changes (by ANOVA) between entry and week 96. Linear models compared WC and self-reported changes.

Results

The study population (n=328) was predominantly male (90%) and White non-Hispanic (44%) with a baseline median age of 36 years and body mass index of 25 kg/m². At week 96, median WC change was +2.8 cm. Of those reporting at week 96, 53% indicated ‘no change/lost’, 39% ‘gained some/somewhat larger’ and 8% ‘gained a lot/much larger’ as their self-reported changes. Trunk fat, VAT and TAT changes differed across self-reported groups (ANOVA P<0.0001 for all), and the group ordering was as expected. WC changes were strongly correlated with CT and DXA changes (trunk fat: ρ=0.72, p<0.0001; VAT: ρ=0.52, p<0.0001; TAT: ρ=0.62, p<0.0001). While WC changes explained a greater proportion of VAT, TAT and trunk fat variation, self-reported changes remained a significant predictor after controlling for WC (p<0.05).

Conclusions

WC and self-reported abdominal changes each correlated directly with imaging-derived abdominal fat measures, and can be used as reliable, affordable tools for central adiposity assessment.

References

Cheruvu

, Holloway

C.J.

Cardiovascular disease in human immunodeficiency virus.

Intern Med J 2014; 44: 315–324.

Currier

J.S.

, Lundgren

J.D.

, Carr

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

Circulation 2008; 118: e29–e35.

Esser

, Gelbrich

, Brockmeyer

Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study.

Clin Res Cardiol 2013; 102: 203–213.

Domingo

, Estrada

, López-Aldeguer

, Villaroya

, Martínez

Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy.

AIDS Rev 2012; 14: 112–123.

Hughes-Austin

J.M.

, Larsen

B.A.

, Allison

M.A.

Visceral adipose tissue and cardiovascular disease risk.

Curr Cardiovasc Risk Rep 2013; 7: 95–101.

McComsey

G.A.

, Kitch

, Sax

P.E.

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

Clin Infect Dis 2011; 53: 185–196.

Martinez

, Gonzalez-Cordon

, Ferrer

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.

Clin Infect Dis 2015; 60: 811–820.

Wronska

, Kmiec

Structural and biochemical characteristics of various white adipose tissue depots.

Acta Physiol (Oxf) 2012; 205: 194–208.

Després

J P.

. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012; 126: 1301–1313.

10.

Katzmarzyk

P.T.

, Heymsfield

S.B.

, Bouchard

Clinical utility of visceral adipose tissue for the identification of cardiometabolic risk in white and African American adults.

Am J Clin Nutr 2013; 97: 480–486.

11.

Fox

C.S.

, Massaro

J.M.

, Hoffmann

Abdominal visceral and subcutaneous adipose tissue compartments association with metabolic risk factors in the Framingham Heart Study.

Circulation 2007; 116: 39–48.

12.

Guaraldi

, Stentarelli

, Zona

Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects.

Atherosclerosis 2010; 208: 222–227.

13.

Guaraldi

, Zona

, Orlando

Progression of coronary artery calcium in men affected by human immunodeficiency virus infection.

Int J Cardiovasc Imaging 2012; 28: 935–941.

14.

Lake

J.E.

, Wohl

, Scherzer

Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study.

AIDS Care 2011; 23: 929–938.

15.

Scherzer

, Heymsfield

S.B.

, Lee

Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection.

AIDS 2011; 25: 1405–1414.

16.

Amato

M.C.

, Guarnotta

, Giordano

Body composition assessment for the definition of cardiometabolic risk.

J Endocrinol Invest 2013; 36: 537–543.

17.

Després

J.P.

, Prud'homme

, Pouliot

M.C.

, Tremblay

, Bouchard

Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men.

Am J Clin Nutr 1991; 54: 471–477.

18.

Direk

, Cecelja

, Astle

The relationship between DXA-based and anthropometric measures of visceral fat and morbidity in women.

BMC Cardiovasc Disord 2013; 13: 25.

19.

Rankinen

, Kim

S.Y.

, Pérusse

, Després

J.P.

, Bouchard

The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis.

Int J Obes Relat Metab Disord 1999; 23: 801–809.

20.

Pouliot

M.C.

, Després

J.P.

, Lemieux

Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women.

Am J Cardiol 1994; 73: 460–468.

21.

Tungsiripat

, O'Riordan

M.A.

, Storer

Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat.

HIV Clin Trials 2009; 10: 314–319.

22.

Abrahams

, Dave

J.A.

, Maartens

, Lesosky

, Levitt

N.S.

The development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settings.

AIDS Res Ther 2014; 11: 26.

23.

Belloso

W.H.

, Quirós

R.E.

, Ivalo

S.A.

Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients.

J Acquir Immune Defic Syndr 2003; 32: 104–111.

24.

Haubrich

R.H.

, Riddler

S.A.

, DiRienzo

Clinical associations of extremity fat loss from ACTG 5142: a prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for antiretroviral therapy (ART) of naive, HIV-1 infected subjects. 15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA.

25.

Lennox

J.L.

, Landovitz

R.J.

, Ribaudo

H.J.

A Phase III comparative study of the efficacy and tolerability of three non-nucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive HIV-1-infected volunteers: a randomized, controlled trial.

Ann Intern Med 2014; 161: 461–471.

26.

Ofotokun

, Na

L.H.

, Landovitz

R.J.

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Clin Infect Dis 2015; 60: 1842–1851.

27.

Stein

J.H.

, Brown

T.T.

, Ribaudo

H.J.

Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection.

AIDS 2013; 27: 929–937.

28.

Kelesidis

, Tran

T.T.T.

, Stein

J.H.

Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s.

Clin Infect Dis 2015; 61: 651–660.

29.

Brown

T.T.

, Chen

, Currier

J.S.

Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1 infected individuals.

J Acquir Immune Defic Syndr 2013; 63: 323–330.

30.

McComsey

G.A.

, Moser

, Currier

Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s.

Clin Infect Dis 2016; 62: 853–862.

31.

CDC. About adult BMI. (Accessed 14 July 2015.) Available from http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/.

32.

Tien

P.C.

, Benson

, Zolopa

A.R.

, Sidney

, Osmond

, Grunfeld

The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics.

Am J Epidemiol 2006; 163: 860–869.

33.

Wen

, Kowaleski-Jones

Sex and ethnic differences in validity of self-reported adult height, weight and body mass index.

Ethn Dis 2012; 22: 72–78.

34.

Krul

A.J.

, Daanen

H.A.M.

, Choi

Self-reported and measured weight, height and body mass index (BMI) in Italy, the Netherlands and North America.

Eur J Public Health 2011; 21: 414–419.

35.

Falutz

, Rosenthall

, Kotler

, Zona

, Guaraldi

Surrogate markers of visceral adipose tissue in treated HIV-infected patients: accuracy of waist circumference determination.

HIV Med 2014; 15: 98–107.

36.

Falutz

, Allas

, Blot

Metabolic effects of a growth hormone–releasing factor in patients with HIV.

N Engl J Med 2007; 357: 2359–2370.

37.

Janiszewski

P.M.

, Ross

, Despres

J-P

Hypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: a cross-sectional study.

PLoS One 2011; 6: e25032.

38.

Klein

, Allison

D.B.

, Heymsfield

S.B.

Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association.

Am J Clin Nutr 2007; 85: 1197–1202.

39.

Mahy

, Autenrieth

C.S.

, Stanecki

, Wynd

Increasing trends in HIV prevalence among people aged 50 years and older: evidence from estimates and survey data.

AIDS 2014; 28: S453–S459.

40.

Koethe

J.R.

, Jenkins

C.A.

, Lau

Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada.

AIDS Res Hum Retroviruses 2016; 32: 50–58.

41.

Reynes

, Trinh

, Pulido

Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS Study.

AIDS Res Hum Retroviruses 2013; 29: 256–265.

42.

Moyle

G.J.

, Hardy

, Farajallah

, DeGrosky

, McGrath

Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naive patients with HIV-1 infection.

Clin Drug Investig 2014; 34: 287–296.